About

Phosplatin Therapeutics was formed to develop and commercialize phosphaplatins, a family of small-molecule compounds designed to replace conventional cytotoxic therapies in the treatment of cancer. 

Phosphaplatins are the result of 30 years of investigation by Dr. Rathindra N. Bose, who is Chairman of the company’s Scientific Advisory Board, and Vice Chancellor for Research at the University of Houston.


Headquarters:

1350 Avenue of the Americas 3rd Fl. 

New York, NY 10019-4703

(646) 380-2441

info@phosplatin.com

 

 
heritage-grid.jpg